Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat
Meditation and psychedelics have played key roles in humankind’s search for self-transcendence and personal change. However, neither their possible synergistic effects, nor related state and trait predictors have been experimentally studied. To elucidate these issues, we administered double-blind th...
Gespeichert in:
Veröffentlicht in: | Scientific reports 2019-10, Vol.9 (1), p.14914-13, Article 14914 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 13 |
---|---|
container_issue | 1 |
container_start_page | 14914 |
container_title | Scientific reports |
container_volume | 9 |
creator | Smigielski, Lukasz Kometer, Michael Scheidegger, Milan Krähenmann, Rainer Huber, Theo Vollenweider, Franz X. |
description | Meditation and psychedelics have played key roles in humankind’s search for self-transcendence and personal change. However, neither their possible synergistic effects, nor related state and trait predictors have been experimentally studied. To elucidate these issues, we administered double-blind the model psychedelic drug psilocybin (315 μg/kg PO) or placebo to meditators (
n
= 39) during a 5-day mindfulness group retreat. Psilocybin increased meditation depth and incidence of positively experienced self-dissolution along the perception-hallucination continuum, without concomitant anxiety. Openness, optimism, and emotional reappraisal were predictors of the acute response. Compared with placebo, psilocybin enhanced post-intervention mindfulness and produced larger positive changes in psychosocial functioning at a 4-month follow-up, which were corroborated by external ratings, and associated with magnitude of acute self-dissolution experience. Meditation seems to enhance psilocybin’s positive effects while counteracting possible dysphoric responses. These findings highlight the interactions between non-pharmacological and pharmacological factors, and the role of emotion/attention regulation in shaping the experiential quality of psychedelic states, as well as the experience of selflessness as a modulator of behavior and attitudes. A better comprehension of mechanisms underlying most beneficial psychedelic experiences may guide therapeutic interventions across numerous mental conditions in the form of psychedelic-assisted applications. |
doi_str_mv | 10.1038/s41598-019-50612-3 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6813317</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2309515095</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-8c6b56f31af89b4f5d26bdba6fa76df5bddc78f6256187ba54f4d61c0ba947083</originalsourceid><addsrcrecordid>eNp9UVtLHDEYDdKiov6BPkigz2Nzn5mXQllaLQh9qc8h193IbDImmdLtr2_cVasvDSH5Luec74MDwAeMrjCiw6fCMB-HDuGx40hg0tEjcEoQ4x2hhLx7FZ-Ai1LuUTucjAyPx-CEYsFGitgp-L3aqKxMdTn8UTWkCFW0cM7OBrNPk4fKLNXt62UpVYXoLMyuzCkWB2uCc9mZjbNuCqbFYUpmp0OE7Sq4DdH6ZYquFLjOaZkbs2an6jl479VU3MXTfwbuvn39ubrpbn9cf199ue0M61ntBiM0F55i5YdRM88tEdpqJbzqhfVcW2v6wQvCBR56rTjzzApskFYj69FAz8Dng-686K2zxsWa1STnHLYq72RSQb7txLCR6_RLigFTivsm8PFJIKeHxZUq79OSY9tZEopGjnl7GoocUCanUrLzLxMwko-GyYNhshkm94ZJ2kiXr3d7oTzb0wD0ACitFdcu_5v9H9m_03ylOQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2309515095</pqid></control><display><type>article</type><title>Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Nature Free</source><source>PubMed Central</source><source>Springer Nature OA/Free Journals</source><source>Free Full-Text Journals in Chemistry</source><creator>Smigielski, Lukasz ; Kometer, Michael ; Scheidegger, Milan ; Krähenmann, Rainer ; Huber, Theo ; Vollenweider, Franz X.</creator><creatorcontrib>Smigielski, Lukasz ; Kometer, Michael ; Scheidegger, Milan ; Krähenmann, Rainer ; Huber, Theo ; Vollenweider, Franz X.</creatorcontrib><description>Meditation and psychedelics have played key roles in humankind’s search for self-transcendence and personal change. However, neither their possible synergistic effects, nor related state and trait predictors have been experimentally studied. To elucidate these issues, we administered double-blind the model psychedelic drug psilocybin (315 μg/kg PO) or placebo to meditators (
n
= 39) during a 5-day mindfulness group retreat. Psilocybin increased meditation depth and incidence of positively experienced self-dissolution along the perception-hallucination continuum, without concomitant anxiety. Openness, optimism, and emotional reappraisal were predictors of the acute response. Compared with placebo, psilocybin enhanced post-intervention mindfulness and produced larger positive changes in psychosocial functioning at a 4-month follow-up, which were corroborated by external ratings, and associated with magnitude of acute self-dissolution experience. Meditation seems to enhance psilocybin’s positive effects while counteracting possible dysphoric responses. These findings highlight the interactions between non-pharmacological and pharmacological factors, and the role of emotion/attention regulation in shaping the experiential quality of psychedelic states, as well as the experience of selflessness as a modulator of behavior and attitudes. A better comprehension of mechanisms underlying most beneficial psychedelic experiences may guide therapeutic interventions across numerous mental conditions in the form of psychedelic-assisted applications.</description><identifier>ISSN: 2045-2322</identifier><identifier>EISSN: 2045-2322</identifier><identifier>DOI: 10.1038/s41598-019-50612-3</identifier><identifier>PMID: 31649304</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/477/2811 ; 692/699/476 ; Anxiety ; Attention - drug effects ; Buddhism ; Depth perception ; Dissolution ; Emotions - drug effects ; Female ; Hallucinogens - adverse effects ; Hallucinogens - pharmacology ; Humanities and Social Sciences ; Humans ; Male ; Meditation ; Meditation - methods ; Meditation - psychology ; Middle Aged ; Mindfulness ; multidisciplinary ; Psilocybin ; Psilocybin - adverse effects ; Psilocybin - pharmacology ; Psychedelic drugs ; Science ; Science (multidisciplinary) ; Social Behavior ; Social interactions ; Synergistic effect ; Therapeutic applications</subject><ispartof>Scientific reports, 2019-10, Vol.9 (1), p.14914-13, Article 14914</ispartof><rights>The Author(s) 2019</rights><rights>2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-8c6b56f31af89b4f5d26bdba6fa76df5bddc78f6256187ba54f4d61c0ba947083</citedby><cites>FETCH-LOGICAL-c474t-8c6b56f31af89b4f5d26bdba6fa76df5bddc78f6256187ba54f4d61c0ba947083</cites><orcidid>0000-0001-9053-6164 ; 0000-0003-1218-0726</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6813317/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6813317/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,41120,42189,51576,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31649304$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Smigielski, Lukasz</creatorcontrib><creatorcontrib>Kometer, Michael</creatorcontrib><creatorcontrib>Scheidegger, Milan</creatorcontrib><creatorcontrib>Krähenmann, Rainer</creatorcontrib><creatorcontrib>Huber, Theo</creatorcontrib><creatorcontrib>Vollenweider, Franz X.</creatorcontrib><title>Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat</title><title>Scientific reports</title><addtitle>Sci Rep</addtitle><addtitle>Sci Rep</addtitle><description>Meditation and psychedelics have played key roles in humankind’s search for self-transcendence and personal change. However, neither their possible synergistic effects, nor related state and trait predictors have been experimentally studied. To elucidate these issues, we administered double-blind the model psychedelic drug psilocybin (315 μg/kg PO) or placebo to meditators (
n
= 39) during a 5-day mindfulness group retreat. Psilocybin increased meditation depth and incidence of positively experienced self-dissolution along the perception-hallucination continuum, without concomitant anxiety. Openness, optimism, and emotional reappraisal were predictors of the acute response. Compared with placebo, psilocybin enhanced post-intervention mindfulness and produced larger positive changes in psychosocial functioning at a 4-month follow-up, which were corroborated by external ratings, and associated with magnitude of acute self-dissolution experience. Meditation seems to enhance psilocybin’s positive effects while counteracting possible dysphoric responses. These findings highlight the interactions between non-pharmacological and pharmacological factors, and the role of emotion/attention regulation in shaping the experiential quality of psychedelic states, as well as the experience of selflessness as a modulator of behavior and attitudes. A better comprehension of mechanisms underlying most beneficial psychedelic experiences may guide therapeutic interventions across numerous mental conditions in the form of psychedelic-assisted applications.</description><subject>631/477/2811</subject><subject>692/699/476</subject><subject>Anxiety</subject><subject>Attention - drug effects</subject><subject>Buddhism</subject><subject>Depth perception</subject><subject>Dissolution</subject><subject>Emotions - drug effects</subject><subject>Female</subject><subject>Hallucinogens - adverse effects</subject><subject>Hallucinogens - pharmacology</subject><subject>Humanities and Social Sciences</subject><subject>Humans</subject><subject>Male</subject><subject>Meditation</subject><subject>Meditation - methods</subject><subject>Meditation - psychology</subject><subject>Middle Aged</subject><subject>Mindfulness</subject><subject>multidisciplinary</subject><subject>Psilocybin</subject><subject>Psilocybin - adverse effects</subject><subject>Psilocybin - pharmacology</subject><subject>Psychedelic drugs</subject><subject>Science</subject><subject>Science (multidisciplinary)</subject><subject>Social Behavior</subject><subject>Social interactions</subject><subject>Synergistic effect</subject><subject>Therapeutic applications</subject><issn>2045-2322</issn><issn>2045-2322</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9UVtLHDEYDdKiov6BPkigz2Nzn5mXQllaLQh9qc8h193IbDImmdLtr2_cVasvDSH5Luec74MDwAeMrjCiw6fCMB-HDuGx40hg0tEjcEoQ4x2hhLx7FZ-Ai1LuUTucjAyPx-CEYsFGitgp-L3aqKxMdTn8UTWkCFW0cM7OBrNPk4fKLNXt62UpVYXoLMyuzCkWB2uCc9mZjbNuCqbFYUpmp0OE7Sq4DdH6ZYquFLjOaZkbs2an6jl479VU3MXTfwbuvn39ubrpbn9cf199ue0M61ntBiM0F55i5YdRM88tEdpqJbzqhfVcW2v6wQvCBR56rTjzzApskFYj69FAz8Dng-686K2zxsWa1STnHLYq72RSQb7txLCR6_RLigFTivsm8PFJIKeHxZUq79OSY9tZEopGjnl7GoocUCanUrLzLxMwko-GyYNhshkm94ZJ2kiXr3d7oTzb0wD0ACitFdcu_5v9H9m_03ylOQ</recordid><startdate>20191024</startdate><enddate>20191024</enddate><creator>Smigielski, Lukasz</creator><creator>Kometer, Michael</creator><creator>Scheidegger, Milan</creator><creator>Krähenmann, Rainer</creator><creator>Huber, Theo</creator><creator>Vollenweider, Franz X.</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-9053-6164</orcidid><orcidid>https://orcid.org/0000-0003-1218-0726</orcidid></search><sort><creationdate>20191024</creationdate><title>Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat</title><author>Smigielski, Lukasz ; Kometer, Michael ; Scheidegger, Milan ; Krähenmann, Rainer ; Huber, Theo ; Vollenweider, Franz X.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-8c6b56f31af89b4f5d26bdba6fa76df5bddc78f6256187ba54f4d61c0ba947083</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>631/477/2811</topic><topic>692/699/476</topic><topic>Anxiety</topic><topic>Attention - drug effects</topic><topic>Buddhism</topic><topic>Depth perception</topic><topic>Dissolution</topic><topic>Emotions - drug effects</topic><topic>Female</topic><topic>Hallucinogens - adverse effects</topic><topic>Hallucinogens - pharmacology</topic><topic>Humanities and Social Sciences</topic><topic>Humans</topic><topic>Male</topic><topic>Meditation</topic><topic>Meditation - methods</topic><topic>Meditation - psychology</topic><topic>Middle Aged</topic><topic>Mindfulness</topic><topic>multidisciplinary</topic><topic>Psilocybin</topic><topic>Psilocybin - adverse effects</topic><topic>Psilocybin - pharmacology</topic><topic>Psychedelic drugs</topic><topic>Science</topic><topic>Science (multidisciplinary)</topic><topic>Social Behavior</topic><topic>Social interactions</topic><topic>Synergistic effect</topic><topic>Therapeutic applications</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Smigielski, Lukasz</creatorcontrib><creatorcontrib>Kometer, Michael</creatorcontrib><creatorcontrib>Scheidegger, Milan</creatorcontrib><creatorcontrib>Krähenmann, Rainer</creatorcontrib><creatorcontrib>Huber, Theo</creatorcontrib><creatorcontrib>Vollenweider, Franz X.</creatorcontrib><collection>Springer Nature OA/Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Scientific reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Smigielski, Lukasz</au><au>Kometer, Michael</au><au>Scheidegger, Milan</au><au>Krähenmann, Rainer</au><au>Huber, Theo</au><au>Vollenweider, Franz X.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat</atitle><jtitle>Scientific reports</jtitle><stitle>Sci Rep</stitle><addtitle>Sci Rep</addtitle><date>2019-10-24</date><risdate>2019</risdate><volume>9</volume><issue>1</issue><spage>14914</spage><epage>13</epage><pages>14914-13</pages><artnum>14914</artnum><issn>2045-2322</issn><eissn>2045-2322</eissn><abstract>Meditation and psychedelics have played key roles in humankind’s search for self-transcendence and personal change. However, neither their possible synergistic effects, nor related state and trait predictors have been experimentally studied. To elucidate these issues, we administered double-blind the model psychedelic drug psilocybin (315 μg/kg PO) or placebo to meditators (
n
= 39) during a 5-day mindfulness group retreat. Psilocybin increased meditation depth and incidence of positively experienced self-dissolution along the perception-hallucination continuum, without concomitant anxiety. Openness, optimism, and emotional reappraisal were predictors of the acute response. Compared with placebo, psilocybin enhanced post-intervention mindfulness and produced larger positive changes in psychosocial functioning at a 4-month follow-up, which were corroborated by external ratings, and associated with magnitude of acute self-dissolution experience. Meditation seems to enhance psilocybin’s positive effects while counteracting possible dysphoric responses. These findings highlight the interactions between non-pharmacological and pharmacological factors, and the role of emotion/attention regulation in shaping the experiential quality of psychedelic states, as well as the experience of selflessness as a modulator of behavior and attitudes. A better comprehension of mechanisms underlying most beneficial psychedelic experiences may guide therapeutic interventions across numerous mental conditions in the form of psychedelic-assisted applications.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>31649304</pmid><doi>10.1038/s41598-019-50612-3</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0001-9053-6164</orcidid><orcidid>https://orcid.org/0000-0003-1218-0726</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2045-2322 |
ispartof | Scientific reports, 2019-10, Vol.9 (1), p.14914-13, Article 14914 |
issn | 2045-2322 2045-2322 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6813317 |
source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Nature Free; PubMed Central; Springer Nature OA/Free Journals; Free Full-Text Journals in Chemistry |
subjects | 631/477/2811 692/699/476 Anxiety Attention - drug effects Buddhism Depth perception Dissolution Emotions - drug effects Female Hallucinogens - adverse effects Hallucinogens - pharmacology Humanities and Social Sciences Humans Male Meditation Meditation - methods Meditation - psychology Middle Aged Mindfulness multidisciplinary Psilocybin Psilocybin - adverse effects Psilocybin - pharmacology Psychedelic drugs Science Science (multidisciplinary) Social Behavior Social interactions Synergistic effect Therapeutic applications |
title | Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T11%3A19%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Characterization%20and%20prediction%20of%20acute%20and%20sustained%20response%20to%20psychedelic%20psilocybin%20in%20a%20mindfulness%20group%20retreat&rft.jtitle=Scientific%20reports&rft.au=Smigielski,%20Lukasz&rft.date=2019-10-24&rft.volume=9&rft.issue=1&rft.spage=14914&rft.epage=13&rft.pages=14914-13&rft.artnum=14914&rft.issn=2045-2322&rft.eissn=2045-2322&rft_id=info:doi/10.1038/s41598-019-50612-3&rft_dat=%3Cproquest_pubme%3E2309515095%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2309515095&rft_id=info:pmid/31649304&rfr_iscdi=true |